Pharmaceuticals

Prescription Orthopedic Drugs Market Anticipated to Record Steady Gains, Advancing to $67.5 Billion by 2030

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the prescription orthopedic drugs market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Prescription Orthopedic Drugs Market be in 2030 compared with 2026?

The size of the prescription orthopedic drugs market has experienced robust growth in recent years. Projections indicate it will expand from $51.06 billion in 2025 to $54.01 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. This historical expansion can be linked to factors such as the high prevalence of arthritis, a rise in orthopedic surgeries, extensive NSAID utilization, joint disorders associated with an aging population, and the increasing availability of orthopedic healthcare facilities.

The prescription orthopedic drugs market is projected to experience robust expansion in the coming years. This market is forecast to reach $67.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.7%. Several factors contribute to this anticipated growth, including an increase in osteoarthritis cases, a rising need for sustained pain management, the broader availability of biologic orthopedic drugs, a higher occurrence of sports injuries, and an uptick in orthopedic drug prescriptions. Key trends expected during this period involve an increasing call for pain management treatments, greater utilization of anti-inflammatory orthopedic medications, a heightened emphasis on addressing chronic joint disorders, an expansion in the use of DMARDs within orthopedics, and a surge in the adoption of combination pain therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21263&type=smp

What Drivers Are Guiding Growth Patterns In The Prescription Orthopedic Drugs Market?

The escalating occurrence of musculoskeletal disorders is anticipated to fuel the expansion of the prescription orthopedic drugs market moving forward. Musculoskeletal disorders (MSDs) are health conditions and injuries that affect the movement and function of the human body’s musculoskeletal system, encompassing muscles, tendons, ligaments, nerves, and joints, resulting in pain and diminished mobility. The rising frequency of these disorders primarily results from factors such as advancing age, occupational activities that involve repetitive motions and uncomfortable postures, lifestyle choices like physical inactivity and poor nutrition, along with genetic predispositions. Prescription orthopedic drugs are crucial in addressing musculoskeletal disorders by easing pain, reducing inflammation, and accelerating the healing process, thereby improving both mobility and overall quality of life. For instance, in March 2023, figures from the Office for Health Improvement & Disparities (UK) revealed that the prevalence of long-term self-reported musculoskeletal (MSK) conditions in individuals aged 16 and over climbed to 17.6% in 2022. Thus, the growing incidence of musculoskeletal disorders is driving the growth of the prescription orthopedic drugs market.

Which Segments Are Driving Activity In The Prescription Orthopedic Drugs Market?

The prescription orthopedic drugs market covered in this report is segmented –

1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioids, Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Other Drug Types

2) By Application: Osteoarthritis, Rheumatoid Arthritis, Osteoporosis, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Celecoxib, Indomethacin

2) By Opioids: Morphine, Oxycodone, Hydrocodone, Fentanyl, Tramadol

3) By Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone, Hydrocortisone, Betamethasone

4) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate, Hydroxychloroquine, Leflunomide, Sulfasalazine, Azathioprine

5) By Other Drug Types: Bisphosphonates, Calcitonin, Monoclonal Antibodies, Muscle Relaxants, Hyaluronic Acid Injections

Which Innovation Trends Are Advancing Developments Within The Prescription Orthopedic Drugs Market?

Leading companies within the prescription orthopedic drugs market are prioritizing the expansion of drug indications, such as extended-indication analgesic formulations, to enhance postoperative pain management across a wider spectrum of orthopedic and soft-tissue procedures. An extended-indication analgesic formulation refers to a pain-relief drug whose approved clinical application has been broadened to cover additional medical procedures, conditions, or patient populations beyond its initial authorization. For example, in January 2023, Heron Therapeutics Inc., a US-based biotechnology company, obtained FDA approval for the expanded use of ZYNRELEF (bupivacaine and meloxicam) in soft tissue and orthopedic procedures, including foot and ankle surgeries. This extended-release solution is specifically designed to offer prolonged pain relief for up to 72 hours, thereby reducing or eliminating the need for opioids post-surgery. The expanded indication now includes additional orthopedic and soft tissue procedures, like foot and ankle surgeries, increasing its applicability in clinical settings. Its innovative dual-drug combination provides both local anesthetic and anti-inflammatory effects, making it a comprehensive choice for managing post-operative pain and improving patient outcomes.

Which Major Firms Are Strengthening Their Position In The Prescription Orthopedic Drugs Market?

Major companies operating in the prescription orthopedic drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck KGaA, AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., UCB S.A., Allergan plc, Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/prescription-orthopedic-drugs-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Prescription Orthopedic Drugs Market?

North America was the largest region in the prescription orthopedic drugs market in 2025. The regions covered in the prescription orthopedic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Prescription Orthopedic Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21263&type=smp

Browse Through More Reports Similar to the Global Prescription Orthopedic Drugs Market 2026, By The Business Research Company

Veterinary Orthopedic Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-orthopedic-medicine-global-market-report

Orthopedic Biomaterials Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthopedic-biomaterials-global-market-report

Orthopedic Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthopedic-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795